³ëº¸·çÇÁ, ¼øÈ¯ ¼º´É ¼ÒÀç È®Àå À§ÇØ Å¸¶ó´Ï½º ÁÖµµ·Î 2100¸¸´Þ·¯ ±Ô¸ðÀÇ ½Ã¸®Áî B ÆÝµù À¯Ä¡
(¸à·ÎÆÄÅ©, ͏®Æ÷´Ï¾Æ=´º½º¿ÍÀ̾î) 2025-07-05
¾¾µð³×Æ®¿÷½º, ¿§Áö ÄÄÇ»ÆÃ Ç÷§Æû ¡®¿§Áö ¾ÖÇø®ÄÉÀ̼ǡ¯ Ãâ½Ã
¿Â¶óÀÎ ºñÁî´Ï½ºÀÇ ¹Îø¼º°ú È¿À²¼º ±Ø´ëÈ
(¼¿ï=´º½º¿ÍÀ̾î) 2024-09-03
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
The agreement builds on Organon¡¯s global product portfolio for conditions that impact women disproportionately. Women are three times more likely to experience migraine than men.[i]
(JERSEY CITY, N.J.=´º½º¿ÍÀ̾î) 2024-08-30
³×½½·¹ÄÚ¸®¾Æ, 2024 ¼¼°è û³âÀÇ ³¯ ¸Â¾Æ ³×½½·¹ÀÇ Ã»³â Áö¿ø Ȱµ¿ ¹× ¼º°ú °øÀ¯
¡®³×½½·¹ ´ÏÁî À¯½º(Nestl
(¼¿ï=´º½º¿ÍÀ̾î) 2024-08-13